ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,221 to 1,240 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
BMD Result Letter and Brochure vs Control: deaths from any cause26 of 3,898

18 of 3,851

0.2 points

-0.1 to 0.6

7,749NCT01507662

Patient Activation After DXA Result Notification

MenACWY-CRM197 + Routine Vaccines (All) vs Routine Vaccines (All): serious adverse events354 of 5,760

114 of 1,968

0.4 points

-0.9 to 1.5

7,728NCT00806195

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

No-intervention Control vs Social Influences School-based Smoking Prevention Curriculum: Number of Participants Smoking Daily at 12th Grade995 of 3,876

976 of 3,847

0.3 points

-1.6 to 2.2

7,723NCT00115869

Hutchinson Smoking Prevention Project

Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality, MI or IDR343 of 3,860

327 of 3,827

0.3 points

-0.9 to 1.6

7,687NCT00305162

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Cangrelor Arm vs Clopidogrel Arm: Incidence of Stroke5 of 3,860

7 of 3,827

-0.1 points

-0.3 to 0.1

7,687NCT00305162

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality34 of 3,860

29 of 3,827

0.1 points

-0.3 to 0.5

7,687NCT00305162

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Cangrelor Arm vs Clopidogrel Arm: Incidence of IDR44 of 3,860

52 of 3,827

-0.2 points

-0.7 to 0.3

7,687NCT00305162

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality or MI321 of 3,860

298 of 3,827

0.5 points

-0.7 to 1.7

7,687NCT00305162

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Cangrelor Arm vs Clopidogrel Arm: Incidence of MI297 of 3,860

276 of 3,827

0.5 points

-0.7 to 1.7

7,687NCT00305162

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

With Previous Treatment vs Without Previous Treatment: Risk Factors for the Proportion of Responders of Tolterodine-Previous Treatment698 of 943

5,753 of 6,736

-11.4 points

-14.4 to -8.6

7,679NCT01488578

Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)

Cangrelor Arm vs Clopidogrel Arm: Incidence of All Cause Mortality116 of 3,851

120 of 3,818

-0.1 points

-0.9 to 0.6

7,669NCT00305162

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Cervarix/Engerix-B A Group vs Cervarix/Engerix-B B Group: Number of Female Subjects With Overall Vaccine Effectiveness Against Genital Infection With HPV-16/18 Types in Cervarix/Engerix-B A Group Versus Cervarix/Engerix-B B Group139 of 3,629

117 of 4,029

0.9 points

0.1 to 1.8

7,658NCT00534638

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Insulin Degludec vs Insulin Glargine: Occurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no)187 of 3,818

252 of 3,819

-1.7 points

-2.8 to -0.7

7,637NCT01959529

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Insulin Degludec vs Insulin Glargine: serious adverse events1,473 of 3,818

1,517 of 3,819

-1.1 points

-3.3 to 1.0

7,637NCT01959529

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Comfort Talk® Training vs Control: No-shows in Q4FY15 = Baseline Quarter (OSU)218 of 4,158

216 of 3,446

-1.0 points

-2.1 to 0.0

7,604NCT02427737

Comfort Talk and Economic Outcomes in MRI

Exemestane vs Anastrozole: Clinical Fracture Rate: Number of Participants With Bone Fractures.358 of 3,789

354 of 3,787

0.1 points

-1.2 to 1.4

7,576NCT00066573

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Exemestane vs Anastrozole: Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence157 of 3,789

164 of 3,787

-0.2 points

-1.1 to 0.7

7,576NCT00066573

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

With Urinary Urgency vs Without Urinary Urgency: Risk Factors for the Proportion of Responders of Tolterodine-Urinary Urgency5,529 of 6,521

829 of 1,043

5.3 points

2.8 to 8.0

7,564NCT01488578

Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)

Clopidogrel + ASA vs Placebo + ASA: Adjudicated Major Bleedings251 of 3,772

162 of 3,782

2.4 points

1.3 to 3.4

7,554NCT00249873

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Clopidogrel + ASA vs Placebo + ASA: Death From Any Cause (Cardiovascular and Noncardiovascular)825 of 3,772

841 of 3,782

-0.4 points

-2.2 to 1.5

7,554NCT00249873

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=62

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01507662-deaths",
        "title": "BMD Result Letter and Brochure vs Control: deaths from any cause",
        "summary": "26 of 3898 against 18 of 3851; risk difference 0.2 points, 95% interval -0.1 to 0.6; NCT01507662, Patient Activation After DXA Result Notification",
        "record": "/library/comparisons/NCT01507662-deaths",
        "nct_id": "NCT01507662",
        "kind": "deaths",
        "participants": 7749,
        "risk_difference": {
          "value": 0.0019959766035995263,
          "lower": -0.0014352939492274092,
          "upper": 0.005526263050830323
        },
        "group_1": "26 of 3,898",
        "group_2": "18 of 3,851",
        "difference": "0.2 points",
        "interval": "-0.1 to 0.6",
        "trial_title": "Patient Activation After DXA Result Notification"
      },
      {
        "id": "NCT00806195-sae",
        "title": "MenACWY-CRM197 + Routine Vaccines (All) vs Routine Vaccines (All): serious adverse events",
        "summary": "354 of 5760 against 114 of 1968; risk difference 0.4 points, 95% interval -0.9 to 1.5; NCT00806195, Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants",
        "record": "/library/comparisons/NCT00806195-sae",
        "nct_id": "NCT00806195",
        "kind": "serious-adverse-events",
        "participants": 7728,
        "risk_difference": {
          "value": 0.0035315040650406443,
          "lower": -0.009141473159875709,
          "upper": 0.015030091227981372
        },
        "group_1": "354 of 5,760",
        "group_2": "114 of 1,968",
        "difference": "0.4 points",
        "interval": "-0.9 to 1.5",
        "trial_title": "Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=63",
  "request_id": "FzoPdvJSOu3MUt7k"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?